Sassafras (Sassafras albidum)

Sassafras (Sassafras albidum) is a North American tree whose root bark contains 85% safrole, a compound banned by the FDA for commercial use due to hepatotoxicity and carcinogenic properties. No clinical studies have documented therapeutic benefits, with research limited to phytochemical analysis identifying 12 alkaloids.

Origin & History

Sassafras albidum is a North American tree from the Lauraceae family whose bark, roots, and wood are traditionally used to produce extracts and essential oils. The plant material is extracted via hydrodistillation or solvent extraction (hexane, chloroform, or dichloromethane) to obtain essential oils containing volatile compounds, alkaloids, and other phytochemicals.

Historical & Cultural Context

The research provided does not contain information about historical traditional medicine applications or which traditional medicine systems utilized Sassafras. No documentation of traditional use duration or cultural context is available in the sources.

Health Benefits

• No clinical health benefits documented - available research focuses only on phytochemical composition analysis
• Chemical analysis identified 12 alkaloids in roots and twigs, though therapeutic effects remain unstudied
• Essential oil contains 85% safrole, a compound with regulatory restrictions due to safety concerns
• No human trials, randomized controlled trials, or meta-analyses available in the research literature
• Current evidence limited to laboratory identification of compounds without efficacy data

How It Works

Sassafras root bark contains safrole as its primary bioactive compound, comprising 85% of the essential oil content. Safrole undergoes hepatic metabolism to form reactive metabolites that can bind to DNA and proteins, leading to hepatocellular damage. The compound also interferes with cytochrome P450 enzyme systems, potentially affecting drug metabolism pathways.

Scientific Research

The provided research contains no human clinical trials, randomized controlled trials, or meta-analyses evaluating Sassafras albidum for therapeutic outcomes. Available literature focuses exclusively on phytochemical identification and composition analysis rather than clinical efficacy studies.

Clinical Summary

No clinical trials have evaluated sassafras for therapeutic applications in humans. Available research consists entirely of phytochemical composition studies that identified 12 alkaloids in roots and twigs. The FDA banned safrole-containing products for human consumption in 1960 due to animal studies demonstrating hepatotoxicity and carcinogenic effects. Current evidence is insufficient to support any health claims for sassafras supplementation.

Nutritional Profile

Sassafras (Sassafras albidum) is used primarily as a flavoring/medicinal herb rather than a nutritional food source, so macronutrient contributions are negligible in typical use quantities. Bioactive compounds dominate its chemical profile: Essential oil composition is characterized by safrole (up to 85% of volatile oil content), with remaining oil fractions including eugenol (~5%), camphor (~3%), alpha-pinene (~2%), and small quantities of asarone, myristicin, and elemicin. Root bark contains approximately 5-9% volatile oil by dry weight, making it the most chemically concentrated plant part. Alkaloid profile includes 12 identified alkaloids in roots and twigs, including boldine, norisoboldine, and reticuline (concentrations not precisely quantified in available literature). Tannin content is present in bark tissues, estimated 3-6% dry weight, contributing astringent properties. Lignans including sesamin have been identified in wood fractions. Mucilaginous polysaccharides are present in young leaves and are used in filé powder (dried ground leaves used in Creole cuisine), which contributes thickening capacity; filé powder delivers negligible calories (~5 kcal per teaspoon). Mineral content has not been systematically quantified. Safrole bioavailability is documented in animal models showing rapid gastrointestinal absorption and hepatic metabolism to reactive epoxide intermediates, which formed the basis for FDA restrictions on safrole use in commercial food products since 1960.

Preparation & Dosage

No clinically studied dosage ranges for Sassafras extracts, powders, or standardized preparations are documented in the available research. Regulatory guidance specifies that safrole content should not exceed 0.01% in consumer products. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified due to lack of clinical research

Safety & Interactions

Sassafras is considered unsafe for human consumption due to its high safrole content, which can cause liver damage and has carcinogenic properties. The FDA prohibits the sale of safrole-containing sassafras products for food or supplement use. Sassafras may interact with medications metabolized by cytochrome P450 enzymes and is contraindicated during pregnancy and breastfeeding. Even small amounts can potentially cause adverse effects including nausea, vomiting, and liver toxicity.